Chikungunya Recombinant Subunit Vaccine
基孔肯雅热重组亚单位疫苗
基本信息
- 批准号:9321278
- 负责人:
- 金额:$ 30万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-07-22 至 2019-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdjuvantAedesAfricaAlphavirusAluminumAmericasAntibody ResponseAntigensAreaArthralgiaAsiaAttenuatedBiochemicalBiotechnologyBloodCategoriesCellsChikungunya virusCollaborationsCountryCulicidaeDataDengue VirusDevelopmentDiseaseDisease OutbreaksDoseEconomicsEpidemicEpitopesExanthemaFeverFormulationGPI-0100GeographyGlycoproteinsGoalsHawaiiHeadacheHumanHuman ResourcesImmune responseImmunizationImmunizeInbred BALB C MiceIndian OceanInfectionInsectaInterventionIslandLatin AmericanMeasuresMedicineMilitary PersonnelMonoclonal AntibodiesMorbidity - disease rateMusOutcomePhase I Clinical TrialsPhotophobiaPopulationPreventive vaccineProductionProtein SubunitsProteinsRecombinant ProteinsRecombinant VaccinesRecombinantsReportingResearchRiskSafetySaponinsSerumSouth AmericanSubunit VaccinesSupportive careSystemTechnologyTestingTherapeuticTissuesVaccinesVirusVirus DiseasesVirus-like particleWest IndiesWest Nile virusWorld Health Organizationbasecell mediated immune responsechikungunyacollegeenv Gene Productsimmunogenicimmunogenicitymouse modelneutralizing antibodypathogenpreclinical studypreventprotective efficacyprotein structurepublic health relevancerecombinant virustransmission processvaccine candidatevaccine developmentvector mosquitovirus envelope
项目摘要
DESCRIPTION (provided by applicant): Chikungunya virus (CHIKV) is an alphavirus classified as a category C priority pathogen that causes fever, rash, and arthralgia in humans. In the past decade, CHIKV outbreaks have spread beyond the endemic regions of Africa and Asia, first to the islands in the Indian Ocean, and most recently to the Americas. The World Health Organization has reported that as of October 2014, over 776,000 suspected cases of Chikungunya have been recorded in the Caribbean islands, Latin American countries and some South American countries. Due to this geographic expansion of its range and the increase in the number of human cases, CHIKV is considered to be a re-emerging pathogen; a contributing factor to this re-emergence is the virus adapting to transmission by Aedes albopictus mosquitoes. Currently, there are no licensed vaccines or therapeutics to protect against infection with CHIKV. As with many viral infections, supportive care is the only available treatment. Given the severe morbidity caused by CHIKV, its swift emergence, and the lack of any targeted interventions, a preventative vaccine would provide an effective means to reduce the burden caused by this disease. This application is directed at the development of a CHIKV recombinant subunit vaccine. There are several candidate vaccines under development using a variety of platform technologies including inactivated viruses, live-attenuated viruses, chimeric live-attenuated viruses, virus- like-particles and subunits. As with all vaccines, and in particula for priority pathogens such as CHIKV which requires BSL-3 handling, a combination of safety and economics in manufacturing are of paramount importance. The proposed recombinant subunit approach provides a means to deliver a safe and stable manufacturing platform and allow for easy adjustment of dosing in order to elicit a robust immune response providing strong protection against CHIKV infection. To accomplish this goal, recombinant subunit proteins focused on specific domains with relevant epitopes from the CHIKV envelope glycoproteins will be evaluated. The Specific Aims of this project are: 1) produce recombinant CHIKV E2 subunit proteins 2) demonstrate immunogenicity of candidate vaccines in mice; and 3) demonstrate protective efficacy of candidate vaccines in mice. To achieve these goals, the recombinant E subunit proteins will be produced in an established stable insect expression system for which multiple IND applications have now been filed. A candidate vaccine will be selected on the basis of a composition that maintains native-like protein structure, and which elicits a relevant and robust immune response that is capable of preventing disease following CHIKV challenge. A collaboration between Hawaii Biotech and Baylor College of Medicine has been established to develop and evaluate a successful a CHIKV vaccine. The development of CHIKV recombinant subunit vaccine would be of great value in slowing the spread of this re-emerging Category C virus and preventing the severe morbidity caused by CHIKV infection.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID E CLEMENTS其他文献
DAVID E CLEMENTS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID E CLEMENTS', 18)}}的其他基金
Development of a Cross-Protective New World Encephalitic Alphavirus Subunit Vaccine
交叉保护性新世界脑炎甲病毒亚单位疫苗的研制
- 批准号:
10696914 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Cross-Protective Multivalent Vaccine for Tick-Borne Flaviviruses
蜱传黄病毒交叉保护性多价疫苗
- 批准号:
10225429 - 财政年份:2015
- 资助金额:
$ 30万 - 项目类别:
Development of a Recombinant Subunit Vaccine for CCHF
CCHF 重组亚单位疫苗的开发
- 批准号:
8252247 - 财政年份:2012
- 资助金额:
$ 30万 - 项目类别:
Development of a Recombinant Subunit Vaccine for CCHF
CCHF 重组亚单位疫苗的开发
- 批准号:
8499241 - 财政年份:2012
- 资助金额:
$ 30万 - 项目类别:
Recombinant Subunit Vaccine For Tick-Borne Encephalitis
蜱传脑炎重组亚单位疫苗
- 批准号:
8143373 - 财政年份:2004
- 资助金额:
$ 30万 - 项目类别:
Evaluation of Immunogenicity : Malaria Subunit Vaccine
免疫原性评价:疟疾亚单位疫苗
- 批准号:
6443267 - 财政年份:2002
- 资助金额:
$ 30万 - 项目类别:
EXPRESSION OF MALARIA MSP-1 P42 C-TERMINAL FRAGMENT
疟疾 MSP-1 P42 C 末端片段的表达
- 批准号:
2646424 - 财政年份:1998
- 资助金额:
$ 30万 - 项目类别:
Development of a MSP1-p42 Subunit Vaccine for Malaria
疟疾 MSP1-p42 亚单位疫苗的开发
- 批准号:
6338185 - 财政年份:1998
- 资助金额:
$ 30万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别: